16 results on '"Shu, Guannan"'
Search Results
2. LRP1 induces anti-PD-1 resistance by modulating the DLL4-NOTCH2-CCL2 axis and redirecting M2-like macrophage polarisation in bladder cancer
- Author
-
Lin, Hansen, Fu, Liangmin, Zhou, Xinwei, Yu, Anze, Chen, Yuhang, Liao, Wuyuan, Shu, Guannan, Zhang, Lizhen, Tan, Lei, Liang, Hui, Wang, Zhu, Deng, Qiong, Wang, Jieyan, Jin, Meiyu, Chen, Zhenhua, Wei, Jinhuan, Cao, Jiazheng, Chen, Wei, Li, Xiaofei, Li, Pengju, Lu, Jun, and Luo, Junhang
- Published
- 2024
- Full Text
- View/download PDF
3. Fatty acids metabolism affects the therapeutic effect of anti-PD-1/PD-L1 in tumor immune microenvironment in clear cell renal cell carcinoma
- Author
-
Lin, Hansen, Fu, Liangmin, Li, Pengju, Zhu, Jiangquan, Xu, Quanhui, Wang, Yinghan, Mumin, Mukhtar Adan, Zhou, Xinwei, Chen, Yuhang, Shu, Guannan, Yao, Gaosheng, Chen, Minyu, Lu, Jun, Zhang, Lizhen, Liu, YuJun, Zhao, Yiqi, Bao, Jiahao, Chen, Wei, Luo, Junhang, Li, Xiaofei, Chen, Zhenhua, and Cao, Jiazheng
- Published
- 2023
- Full Text
- View/download PDF
4. Correction: CircNTNG1 inhibits renal cell carcinoma progression via HOXA5-mediated epigenetic silencing of Slug
- Author
-
Liang, Yanping, Cen, Junjie, Huang, Yong, Fang, Yong, Wang, Yunfei, Shu, Guannan, Pan, Yihui, Huang, Kangbo, Dong, Jiaqi, Zhou, Mi, Xu, Yi, Luo, Junhang, Liu, Min, and Zhang, Jiaxing
- Published
- 2023
- Full Text
- View/download PDF
5. CircNTNG1 inhibits renal cell carcinoma progression via HOXA5-mediated epigenetic silencing of Slug
- Author
-
Liang, Yanping, Cen, Junjie, Huang, Yong, Fang, Yong, Wang, Yunfei, Shu, Guannan, Pan, Yihui, Huang, Kangbo, Dong, Jiaqi, Zhou, Mi, Xu, Yi, Luo, Junhang, Liu, Min, and Zhang, Jiaxing
- Published
- 2022
- Full Text
- View/download PDF
6. N6-methyladenosine modification of circMARK2 enhances cytoplasmic export and stabilizes LIN28B, contributing to the progression of Wilms tumor.
- Author
-
Shu, Guannan, Zhao, Zhang, Zhao, Tianxin, Deng, Changmi, Zhu, Jiangquan, Han, Yufeng, Chen, Minyu, Jing, Jiajia, Bai, Gaochen, Li, Dian, Li, Feng, He, Jing, Fu, Wen, and Liu, Guochang
- Subjects
- *
NEPHROBLASTOMA , *CANCER invasiveness , *CIRCULAR RNA , *RENAL cancer , *IMMUNOSTAINING , *PEDIATRIC nephrology - Abstract
Background: The potential involvement of circular RNAs (circRNAs) and N6-methyladenosine (m6A) modification in the progression of Wilms tumor (WT) has not been fully elucidated. This study investigates the regulatory mechanisms and clinical significance of m6A-modified circMARK2 and its role in WT progression. Methods: We identified dysregulated circRNAs through deep sequencing and validated their expression by qRT-PCR in WT tissues. The biological functions of circMARK2 were assessed using clone formation, transwell migration, and orthotopic animal models. To dissect the underlying mechanisms, we employed RNA immunoprecipitation, RNA pull-down, dual-luciferase reporter assays, Western blotting, and immunofluorescence and immunohistochemical staining. Results: CircMARK2, upregulated in WT tissues, was found to be m6A-modified and promoted cytoplasmic export. It facilitated WT progression by stabilizing LIN28B mRNA through the circMARK2/IGF2BP2 interaction. In vitro and in vivo studies demonstrated that circMARK2 enhances the malignant behavior of WT cells. Clinically, higher circMARK2 levels in tumor tissues of WT patients were linked to increased tumor aggressiveness and reduced survival rates. Conclusions: Our study provides the first comprehensive evidence that m6A-modified circMARK2 contributes to WT progression by enhancing LIN28B mRNA stability, promoting cellular aggressiveness. CircMARK2 emerges as a potential biomarker for prognosis and a promising target for therapeutic intervention in WT, underscoring the clinical relevance of m6A modification in pediatric renal cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Circular RNA circSDHC serves as a sponge for miR-127-3p to promote the proliferation and metastasis of renal cell carcinoma via the CDKN3/E2F1 axis
- Author
-
Cen, Junjie, Liang, Yanping, Huang, Yong, Pan, Yihui, Shu, Guannan, Zheng, Zhousan, Liao, Xiaozhong, Zhou, Mi, Chen, Danlei, Fang, Yong, Chen, Wei, Luo, Junhang, and Zhang, Jiaxing
- Published
- 2021
- Full Text
- View/download PDF
8. EGCG‐LYS Fibrils‐Mediated CircMAP2K2 Silencing Decreases the Proliferation and Metastasis Ability of Gastric Cancer Cells in Vitro and in Vivo.
- Author
-
Dong, Jiaqi, Zheng, Zhousan, Zhou, Mi, Wang, Yunfei, Chen, Jiajie, Cen, Junjie, Cao, Tiefeng, Yang, Taowei, Xu, Yi, Shu, Guannan, Lu, Xuanxuan, and Liang, Yanping
- Subjects
CIRCULAR RNA ,STOMACH cancer ,CANCER cells ,GENE silencing ,SMALL interfering RNA ,METASTASIS ,NANOCARRIERS - Abstract
Aberrant expression of circular RNAs (circRNAs) has been reported to play an important biological regulatory role in gastric cancer (GC). For the purpose of silencing cancer‐related genes, a new approach for cancer treatment using nanocarriers to deliver siRNA has been proposed. In this study, abundantly expressed circMAP2K2 (hsa_circRNA_102415) is identified in GC cells. CircMAP2K2 regulates the PCBP1/GPX1 axis through proteasome‐mediated degradation, which further mediates the activation of the AKT/GSK3β/epithelial‐to‐mesenchymal transition (EMT) signaling pathway and enhances the proliferation and metastatic ability of GC cells. To establish novel GC treatment, epigallocatechin‐3‐gallate‐lysozyme (EGCG‐LYS) fibrils are synthesized, and in vitro experiments demonstrate that EGCG‐LYS has a higher siRNA delivery efficiency than Lipofectamine 2000 (lipo2000), which effectively silences the expression of circMAP2K2. Further studies show that EGCG‐LYS carrying siRNA can successfully achieve lysosome escape, which allows it to be located in the cytoplasm to achieve post‐transcriptional gene silencing. In addition, EGCG‐LYS carrying si‐circMAP2K2 has good circulating stability, excellent biosafety and antitumor ability in vivo. The EGCG‐LYS fibrils delivery system provides a new tool and approach for the treatment of GC. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Hsa_circ_0057105 modulates a balance of epithelial‐mesenchymal transition and ferroptosis vulnerability in renal cell carcinoma.
- Author
-
Cen, Junjie, Liang, Yanping, Feng, Zihao, Chen, Xu, Chen, Jinlong, Wang, Yinghan, Zhu, Jiangquan, Xu, Quanhui, Shu, Guannan, Zheng, Wenbin, Liang, Hui, Wang, Zhu, Deng, Qiong, Cao, Jiazheng, Luo, Junhang, Jin, Xiaohan, and Huang, Yong
- Subjects
EPITHELIAL-mesenchymal transition ,GENE expression ,FLUORESCENCE in situ hybridization ,CIRCULAR RNA ,ANIMAL experimentation - Abstract
Background: The incidence of renal cell carcinoma (RCC) has increased in recent years. Metastatic RCC is common and remains a major cause of mortality. A regulatory role for circular RNAs (circRNAs) in the occurrence and progression of RCC has been identified, but their function, molecular mechanisms, and potential clinical applications remain poorly understood. Methods: High‐throughput RNA sequencing was used to explore the differential expression of circRNAs and their related pathways in RCC patients. Transwell and CCK‐8 assays were used to assess the function of hsa_circ_0057105 in RCC cells. The clinical relevance of hsa_circ_0057105 was evaluated in a cohort of RCC patients. The hsa_circ_0057105 regulatory axis was defined using RNA pull‐down, luciferase reporter assays, and fluorescence in situ hybridization assays, and the in vivo effect of hsa_circ_0057105 was validated using animal experiments. Results: Single‐sample gene set enrichment analysis and correlation analysis of RNA‐seq data showed that hsa_circ_0057105 was potentially oncogenic and may serve to regulate epithelial‐mesenchymal transition (EMT) activation in RCC. Hsa_circ_0057105 expression was associated with advanced TNM stages and was an independent prognostic factor for poor RCC patient survival. Phenotypic studies show that hsa_circ_0057105 can enhance the migration and invasion abilities of RCC cells. Further, hsa_circ_0057105 was shown to inhibit the expression of miR‐577, a miRNA that regulated the expression of both COL1A1, which induced EMT activation, and VDAC2, which modulated ferroptosis sensitivity. The dual regulatory roles of hsa_circ_0057105 on EMT and ferroptosis sensitivity were verified using rescue experiments. Animal studies confirmed that hsa_circ_0057105 increased the metastatic ability and ferroptosis sensitivity of RCC cells in vivo. Conclusions: In RCC, hsa_circ_0057105 regulates COL1A1 and VDAC2 expression through its sponge effect on miR‐577, acting like a 'double‐edged sword'. These findings provide new insight into the relationship between EMT and ferroptosis in RCC and provide potential biomarkers for RCC surveillance and treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. EHBP1L1 Drives Immune Evasion in Renal Cell Carcinoma through Binding and Stabilizing JAK1.
- Author
-
Pan, Yihui, Shu, Guannan, Fu, Liangmin, Huang, Kangbo, Zhou, Xinwei, Gui, Chengpeng, Liu, Huashan, Jin, Xiaohan, Chen, Minyu, Li, Pengju, Cen, Junjie, Feng, Zihao, Lu, Jun, Chen, Zhenhua, Li, Jiaying, Xu, Quanhui, Wang, Yinghan, Liang, Hui, Wang, Zhu, and Deng, Qiong
- Subjects
- *
RENAL cell carcinoma , *IMMUNE checkpoint proteins , *TUMOR growth , *CELLULAR immunity , *TUMOR microenvironment - Abstract
High lymphocyte infiltration and immunosuppression characterize the tumor microenvironment (TME) in renal cell carcinoma (RCC). There is an urgent need to elucidate how tumor cells escape the immune attack and to develop novel therapeutic targets to enhance the efficacy of immune checkpoint blockade (ICB) in RCC. Overactivated IFN‐γ‐induced JAK/STAT signaling involves in such TME, but the underlying mechanisms remain elusive. Here, EH domain‐binding protein 1‐like protein 1 (EHBP1L1) is identified as a crucial mediator of IFN‐γ/JAK1/STAT1/PD‐L1 signaling in RCC. EHBP1L1 is highly expressed in RCC, and high EHBP1L1 expression levels are correlated with poor prognosis and resistance to ICB. EHBP1L1 depletion significantly inhibits tumor growth, which is attributed to enhanced CD8+ T cell‐mediated antitumor immunity. Mechanistically, EHBP1L1 interacts with and stabilizes JAK1. By competing with SOCS1, EHBP1L1 protects JAK1 from proteasomal degradation, which leads to elevated JAK1 protein levels and JAK1/STAT1/PD‐L1 signaling activity, thereby forming an immunosuppressive TME. Furthermore, the combination of EHBP1L1 inhibition and ICB reprograms the immunosuppressive TME and prevents tumor immune evasion, thus significantly reinforcing the therapeutic efficacy of ICB in RCC patient‐derived xenograft (PDX) models. These findings reveal the vital role of EHBP1L1 in immune evasion in RCC, which may be a potential complement for ICB therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
11. Chitosan‐Gelatin‐EGCG Nanoparticle‐Meditated LncRNA TMEM44‐AS1 Silencing to Activate the P53 Signaling Pathway for the Synergistic Reversal of 5‐FU Resistance in Gastric Cancer.
- Author
-
Zhou, Mi, Dong, Jiaqi, Huang, Junqing, Ye, Wen, Zheng, Zhousan, Huang, Kangbo, Pan, Yihui, Cen, Junjie, Liang, Yanping, Shu, Guannan, Ye, Sheng, Lu, Xuanxuan, and Zhang, Jiaxing
- Subjects
STOMACH cancer ,GENE silencing ,SMALL interfering RNA ,FLUOROURACIL ,CELLULAR signal transduction ,LINCRNA ,NANOSATELLITES - Abstract
Chemoresistance is one of the leading causes of therapeutic failure in gastric cancer (GC) treatment. Recent studies have shown lncRNAs play pivotal roles in regulating GC chemoresistance. Nanocarriers delivery of small interfering RNAs (siRNAs) to silence cancer‐related genes has become a novel approach to cancer treatment research. However, finding target genes and developing nanosystems capable of selectively delivering siRNAs for disease treatment remains a challenge. In this study, a novel lncRNA TMEM44‐AS1 that is related to 5‐FU resistance is identified. TMEM44‐AS1 has the ability to bind to and sponge miR‐2355‐5p, resulting in the upregulated PPP1R13L expression and P53 pathway inhibition. Next, a new nanocarrier called chitosan‐gelatin‐EGCG (CGE) is developed, which has a higher gene silencing efficiency than lipo2000, to aid in the delivery of a si‐TMEM44‐AS1 can efficiently silence TMEM44‐AS1 expression to synergistically reverse 5‐FU resistance in GC, leading to a markedly enhanced 5‐FU therapeutic effect in a xenograft mouse model of GC. These findings indicate that TMEM44‐AS1 may estimate 5‐FU therapy outcome among GC cases, and that systemic si‐TMEM44‐AS1 delivery combined with 5‐FU therapy is significant in the treatment of patients with recurrent GC. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
12. PABPC1L Induces IDO1 to Promote Tryptophan Metabolism and Immune Suppression in Renal Cell Carcinoma.
- Author
-
Shu G, Chen M, Liao W, Fu L, Lin M, Gui C, Cen J, Lu J, Chen Z, Wei J, Chen W, Wang Y, Zhu J, Zhao T, Liu X, Jing J, Liu GC, Pan Y, Luo J, and Zhang J
- Subjects
- Animals, Humans, Mice, Cell Line, Tumor, Gene Expression Regulation, Neoplastic, Immune Checkpoint Inhibitors pharmacology, Immune Checkpoint Inhibitors therapeutic use, Janus Kinase 2 metabolism, STAT1 Transcription Factor metabolism, STAT1 Transcription Factor genetics, Tumor Microenvironment immunology, Xenograft Model Antitumor Assays, Carcinoma, Renal Cell immunology, Carcinoma, Renal Cell metabolism, Carcinoma, Renal Cell pathology, Carcinoma, Renal Cell genetics, Carcinoma, Renal Cell drug therapy, Indoleamine-Pyrrole 2,3,-Dioxygenase metabolism, Indoleamine-Pyrrole 2,3,-Dioxygenase genetics, Kidney Neoplasms immunology, Kidney Neoplasms metabolism, Kidney Neoplasms pathology, Kidney Neoplasms genetics, Kidney Neoplasms drug therapy, Tryptophan metabolism
- Abstract
The tumor microenvironment (TME) in renal cell carcinomas (RCC) is marked by substantial immunosuppression and immune resistance despite having extensive T-cell infiltration. Elucidation of the mechanisms underlying immune evasion could help identify therapeutic strategies to boost the efficacy of immune checkpoint blockade (ICB) in RCC. This study uncovered a mechanism wherein the polyadenylate-binding protein PABPC1L modulates indoleamine 2,3-dioxygenase 1 (IDO1), a prospective target for immunotherapy. PABPC1L was markedly upregulated in RCC, and high PABPC1L expression correlated with unfavorable prognosis and resistance to ICB. PABPC1L bolstered tryptophan metabolism by upregulating IDO1, inducing T-cell dysfunction and Treg infiltration. PABPC1L enhanced the stability of JAK2 mRNA, leading to increased JAK2-STAT1 signaling that induced IDO1 expression. Additionally, PABPC1L-induced activation of the JAK2-STAT1 axis created a positive feedback loop to promote PABPC1L transcription. Conversely, loss of PABPC1L diminished IDO1 expression, mitigated cytotoxic T-cell suppression, and enhanced responsiveness to anti-PD-1 therapy in patient-derived xenograft models. These findings reveal the crucial role of PABPC1L in facilitating immune evasion in RCC and indicate that inhibiting PABPC1L could be a potential immunotherapeutic approach in combination with ICB to improve patient outcomes., Significance: PABPC1L functions as a key factor in renal cell carcinoma immune evasion, enhancing IDO1 and impeding T-cell function, and represents a potential target to enhance the efficacy of immune checkpoint blockade therapy., (©2024 The Authors; Published by the American Association for Cancer Research.)
- Published
- 2024
- Full Text
- View/download PDF
13. Bladder cancer intrinsic LRFN2 drives anticancer immunotherapy resistance by attenuating CD8 + T cell infiltration and functional transition.
- Author
-
Yu A, Hu J, Fu L, Huang G, Deng D, Zhang M, Wang Y, Shu G, Jing L, Li H, Chen X, Yang T, Wei J, Chen Z, Zu X, and Luo J
- Subjects
- Humans, Biological Assay, Cell Differentiation, Immunotherapy, Membrane Glycoproteins, Nerve Tissue Proteins, Tumor Microenvironment, Drug Resistance, Neoplasm, CD8-Positive T-Lymphocytes, Urinary Bladder Neoplasms drug therapy
- Abstract
Background: Immune checkpoint inhibitor (ICI) therapy improves the survival of patients with advanced bladder cancer (BLCA); however, its overall effectiveness is limited, and many patients still develop immunotherapy resistance. The leucine-rich repeat and fibronectin type-III domain-containing protein (LRFN) family has previously been implicated in regulating brain dysfunction; however, the mechanisms underlying the effect of LRFN2 on the tumor microenvironment (TME) and immunotherapy remain unclear., Methods: Here we combined bulk RNA sequencing, single-cell RNA sequencing, ProcartaPlex multiple immunoassays, functional experiments, and TissueFAXS panoramic tissue quantification assays to demonstrate that LRFN2 shapes a non-inflammatory TME in BLCA., Results: First, comprehensive multiomics analysis identified LRFN2 as a novel immunosuppressive target specific to BLCA. We found that tumor-intrinsic LRFN2 inhibited the recruitment and functional transition of CD8
+ T cells by reducing the secretion of pro-inflammatory cytokines and chemokines, and this mechanism was verified in vitro and in vivo. LRFN2 restrained antitumor immunity by inhibiting the infiltration, proliferation, and differentiation of CD8+ T cells in vitro. Furthermore, a spatial exclusivity relationship was observed between LRFN2+ tumor cells and CD8+ T cells and cell markers programmed cell death-1 (PD-1) and T cell factor 1 (TCF-1). Preclinically, LRFN2 knockdown significantly enhanced the efficacy of ICI therapy. Clinically, LRFN2 can predict immunotherapy responses in real-world and public immunotherapy cohorts. Our results reveal a new role for LRFN2 in tumor immune evasion by regulating chemokine secretion and inhibiting CD8+ T-cell recruitment and functional transition., Conclusions: Thus, LRFN2 represents a new target that can be combined with ICIs to provide a potential treatment option for BLCA., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)- Published
- 2023
- Full Text
- View/download PDF
14. Exosomal circSPIRE1 mediates glycosylation of E-cadherin to suppress metastasis of renal cell carcinoma.
- Author
-
Shu G, Lu X, Pan Y, Cen J, Huang K, Zhou M, Lu J, Dong J, Han H, Chen W, Lin J, Luo J, and Zhang J
- Subjects
- Animals, Humans, Cadherins genetics, Cadherins metabolism, Cell Line, Tumor, Cell Movement genetics, Cell Proliferation, Disease Models, Animal, Gene Expression Regulation, Neoplastic, Glycosylation, Neoplasm Recurrence, Local genetics, RNA, Circular genetics, RNA, Circular metabolism, Carcinoma, Renal Cell pathology, Kidney Neoplasms pathology, MicroRNAs genetics
- Abstract
Metastasis is the main cause of mortality in renal cell carcinoma (RCC). Circular RNAs (circRNAs) involvement in RCC metastasis has been described, although the underlying mechanisms remain unknown. We evaluated recurring lung-metastasis cases using patient-derived xenograft models and isolated a highly metastatic clone. CircSPIRE1 was identified as a metastasis-inhibiting circRNA in clinical cohort and xenograft models. Mechanistically, circSPIRE1 suppressed mesenchymal state through regulating ELAV like RNA binding protein 1-mRNA binding, and upregulating polypeptide N-acetylgalactosaminyltransferase 3 (GALNT3) and KH domain RNA binding protein (QKI) expression. GALNT3 promoted glycosylation and cytomembrane localization of E-cadherin. QKI formed a positive feedback loop to enhance circSPIRE1 expression. Meanwhile, exosomal circSPIRE1 suppressed angiogenesis and vessel permeability. Our work reveals a non-canonical route for circRNAs in RCC to suppress metastasis. Furthermore, a nanomedicine consisting of circSPIRE1 plasmid suppressed metastasis formation. In conclusion, circSPIRE1 may be a predictor of metastasis and a potential therapeutic target of metastatic RCC., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
15. Extracellular Vesicle-Mediated Transfer of LncRNA IGFL2-AS1 Confers Sunitinib Resistance in Renal Cell Carcinoma.
- Author
-
Pan Y, Lu X, Shu G, Cen J, Lu J, Zhou M, Huang K, Dong J, Li J, Lin H, Song H, Xu Q, Han H, Chen Z, Chen W, Luo J, Wei J, and Zhang J
- Subjects
- Humans, Sunitinib pharmacology, Sunitinib therapeutic use, Cell Line, Tumor, Drug Resistance, Neoplasm genetics, Cell Proliferation, Gene Expression Regulation, Neoplastic, Nuclear Proteins metabolism, Carcinoma, Renal Cell drug therapy, Carcinoma, Renal Cell genetics, Carcinoma, Renal Cell pathology, RNA, Long Noncoding genetics, RNA, Long Noncoding metabolism, Kidney Neoplasms drug therapy, Kidney Neoplasms genetics, Kidney Neoplasms pathology, Extracellular Vesicles metabolism
- Abstract
Sunitinib resistance remains a serious challenge to the treatment of advanced and metastatic renal cell carcinoma (RCC), yet the mechanisms underlying this resistance are not fully understood. Here, we report that the long noncoding RNA IGFL2-AS1 is a driver of therapy resistance in RCC. IGFL2-AS1 was highly upregulated in sunitinib-resistant RCC cells and was associated with poor prognosis in patients with clear cell RCC (ccRCC) who received sunitinib therapy. IGFL2-AS1 enhanced TP53INP2 expression by competitively binding to hnRNPC, a multifunctional RNA-binding protein that posttranscriptionally suppresses TP53INP2 expression through alternative splicing. Upregulated TP53INP2 enhanced autophagy and ultimately led to sunitinib resistance. Meanwhile, IGFL2-AS1 was packaged into extracellular vesicles through hnRNPC, thus transmitting sunitinib resistance to other cells. N6-methyladenosine modification of IGFL2-AS1 was critical for its interaction with hnRNPC. In a patient-derived xenograft model of sunitinib-resistant ccRCC, injection of chitosan-solid lipid nanoparticles containing antisense oligonucleotide-IGFL2-AS1 successfully reversed sunitinib resistance. These findings indicate a novel molecular mechanism of sunitinib resistance in RCC and suggest that IGFL2-AS1 may serve as a prognostic indicator and potential therapeutic target to overcome resistance., Significance: Extracellular vesicle-packaged IGFL2-AS1 promotes sunitinib resistance by regulating TP53INP2-triggered autophagy, implicating this lncRNA as a potential therapeutic target in renal cell carcinoma., (©2022 The Authors; Published by the American Association for Cancer Research.)
- Published
- 2023
- Full Text
- View/download PDF
16. MRI tracking of autologous pancreatic progenitor-derived insulin-producing cells in monkeys.
- Author
-
Zou C, Lu Y, Teng X, Wang S, Sun X, Huang F, Shu G, Huang X, Guo H, Chen Z, Zhang J, and Zhang YA
- Subjects
- Animals, C-Peptide blood, Cell Differentiation, Contrast Media administration & dosage, Contrast Media chemistry, Diabetes Mellitus, Type 1 blood, Diabetes Mellitus, Type 1 pathology, Disease Models, Animal, Ferric Compounds administration & dosage, Ferric Compounds chemistry, Humans, Macaca fascicularis, Magnetite Nanoparticles administration & dosage, Magnetite Nanoparticles chemistry, Mesenchymal Stem Cell Transplantation methods, Pancreatic Polypeptide-Secreting Cells drug effects, Transplantation, Autologous, Cell Tracking methods, Diabetes Mellitus, Type 1 diagnostic imaging, Diabetes Mellitus, Type 1 therapy, Magnetic Resonance Imaging, Pancreatic Polypeptide-Secreting Cells cytology
- Abstract
Insulin-producing cells (IPCs) derived from a patient's own stem cells offer great potential for autologous transplantation in diabetic patients. However, the limited survival of engrafted cells remains a bottleneck in the application of this strategy. The present study aimed to investigate whether nanoparticle-based magnetic resonance (MR) tracking can be used to detect the loss of grafted stem cell-derived IPCs in a sensitive and timely manner in a diabetic monkey model. Pancreatic progenitor cells (PPCs) were isolated from diabetic monkeys and labeled with superparamagnetic iron oxide nanoparticles (SPIONs). The SPION-labeled cells presented as hypointense signals on MR imaging (MRI). The labeling procedure did not affect the viability or IPC differentiation of PPCs. Importantly, the total area of the hypointense signal caused by SPION-labeled IPCs on liver MRI decreased before the decline in C-peptide levels after autotransplantation. Histological analysis revealed no detectable immune response to the grafts and many surviving insulin- and Prussian blue-positive cell clusters on liver sections at one year post-transplantation. Collectively, this study demonstrates that SPIO nanoparticles can be used to label stem cells for noninvasive, sensitive, longitudinal monitoring of stem cell-derived IPCs in large animal models using a conventional MR imager.
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.